
Viridian Therapeutics (VRDN) Stock Forecast & Price Target
Viridian Therapeutics (VRDN) Analyst Ratings
Bulls say
Viridian Therapeutics Inc. is poised for a positive financial outlook, driven by promising clinical execution and improved investor sentiment, as evidenced by a significant target price increase. The company's lead product candidate, Veligrotug, has shown best-in-class potential in treating thyroid eye disease, demonstrating similar efficacy to Tepezza with enhanced patient quality of life measures and a favorable safety profile. Additionally, the introduction of VRDN-003, a subcutaneous offering, is expected to expand Viridian's market share and treatment accessibility, further solidifying its competitive positioning in the thyroid eye disease space.
Bears say
The analysis suggests a negative outlook on Viridian Therapeutics's stock due to several potential risks that could significantly impact its valuation. A delayed launch of Veligrotug could result in a valuation decrease of approximately $4 per share, while failure in key studies could lead to a substantial drop of around $14 per share, indicating a potential 30% downside risk. Furthermore, challenges related to intellectual property protection and competition from well-capitalized peers, combined with potential manufacturing and regulatory setbacks, exacerbate concerns about the company's ability to successfully execute its commercialization strategy.
This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viridian Therapeutics (VRDN) Analyst Forecast & Price Prediction
Start investing in Viridian Therapeutics (VRDN)
Order type
Buy in
Order amount
Est. shares
0 shares